Of the 63 patients with ≥ 12 months follow-up (including patients that withdrew early), ORR was 98.4% (62/93)and 87.3%(55/63)reached sCR/CR. ![]() In 89 patients without prior CAR-T therapy, ORR was 98.9% (88/89), including 78.7% (70/89) of patients reaching CR/sCR. 82.4% (95%CI: 70.90-89.72%) of patients achieved sustained MRD negativity over 12 months and the median duration of MRD negativity was not reached. 95.0% (96/101) of patients achieved minimal residual disease (MRD) negativity, and all CR/sCR patients achieved MRD negativity. The median duration of response (DOR) and median progression free survival (PFS) have not been reached. The median time to response(mTTR) was 16 days (range 11-179). This study enrolled RRMM patients who received ≥ 3 lines of prior therapies containing at least a proteasome inhibitor and an immunomodulatory agent and were refractory to their last line of treatment (ChiCTR1800018137, NCT05066646).Īs of the data cutoff date of September 9th, 2022, a total of 103 patients received CT103A at 1.0×10 6 CAR-T cells/kg with the median follow-up of 13.8 months (range 0.4, 27.2) and median prior four lines of therapy (range 3,23).Īmong the 103 patients, 68.9% (71/103) had high-risk cytogenetic abnormalities per mSMART 3.0, 12.6%(13/103)had extramedullary multiple myeloma (EMM), and 11.7%(12/103)had received prior CAR-T therapy.Įquecabtagene Autoleucel showed deepening and durable efficacy: Among the 101 evaluable patients, the overall response rate (ORR) was 96.0% (97/101), with 91.1% (92/101) of those patients achieving very good partial response (VGPR) or deeper responses, and the stringent complete response/ complete response (sCR/CR) rate was 74.3% (75/101). The updated data showed long-term follow-up efficacy and safety of the Phase 1b/2 study (FUMANBA-1) conducted in 14 centers in China. ![]() Venue: McCormick Place, Chicago, Illinois, United States + Online Session date and Time: Monday, June 5, 2023, at 8:00 AM - 10:00 AM CDT Session Title:Hematologic Malignancies-Plasma Cell Dyscrasia Presentation Title: CT103A, a novel fully human BCMA-targeting CAR-T therapy, in patients with relapsed/refractory multiple myeloma: updated long-term follow-up results of phase 1b/2 study (FUMANBA-1) ![]() ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, and IASO Biotechnology ("IASO Bio"), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, today jointly announced that the updated data from Phase 1b/2 study of Equecabtagene Autoleucel (Innovent R&D code: IBI326, IASO Bio R&D code: CT103A), a fully-human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed and/or refractory multiple myeloma (RRMM), was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 2-6, 2023. and SUZHOU, China, J/PRNewswire/ - Innovent Biologics, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |